ArticleBMC cancer2021

Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy.

Peng-Chan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.